<DOC>
	<DOCNO>NCT02754154</DOCNO>
	<brief_summary>The purpose study compare risk major bleed event among nonvalvular atrial fibrillation patient treat warfarin , apixaban , dabigatran rivaroxaban .</brief_summary>
	<brief_title>Real-World Comparative Observational Study Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients â‰¥18 year old index date At least 1 diagnosis atrial fibrillation 12 month prior index date , identify medical claim At least one year baseline period continuous enrollment least 12 month prior index date Individuals NVAF use oral anticoagulant ( i.e. , warfarin , dabigatran , rivaroxaban apixaban ) within study period begin Jan 1 , 2012 December 31 , 2013 last date last data cut available time execution study Patients evidence valvular heart disease , thyrotoxicosis , pericarditis , mitral stenosis , Venous thromboembolism ( VTE ) , heart surgery , endocarditis baseline period time prior index date Patients evidence pregnancy time baseline exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>